Upadacitinib

Independent reference data for Upadacitinib (CAS 1310726-60-3), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Upadacitinib is a new FDA-approved second-line agent for treating moderate to severe active rheumatoid arthritis (RA) in patients who have not shown an adequate response or intolerance to the first-line agent, methotrexate. This agent is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme. Upadacitinib received FDA approval on August 16, 2019, based on positive and promising results from its multinational phase III trials in subjects with moderate to severe rheumatoid arthritis.Upadacitinib is an oral selective inhibitor of Janus associated kinase 1 (JAK-1) that is used in the therapy of moderate-to-severe rheumatoid arthritis. Upadacitinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.

Synonyms and trade names

Upadacitinib; 1310726-60-3; ABT-494; Upadacitinib anhydrous; 4RA0KN46E0; DTXSID901027919; upadacitinibum; RefChem:57163; L04AA44; DTXCID401513480; Rinvoq; ABT 494; EX-A1628; DB15091; ABBV-599 COMPONENT UPADACITINIB; UNII-4RA0KN46E0

What the public record says

Upadacitinib · CAS 1310726-60-3 · C17H19F3N6O. UNII 4RA0KN46E0. Boiling Point: 189; Melting Point: 16-19.

Source: PubChem / Wikidata; the batch COA governs where values differ.